Potential benefit and lack of serious risk from corticosteroids in drug‐induced liver injury: An international, multicentre, propensity score‐matched analysis

The use of corticosteroids to treat patients with idiosyncratic drug‐induced liver injury (DILI) relies on empirical clinical decisions.

• Publication year

  2022

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2022-12-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.17373PMID 36547393
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial

  2022cited by this paper
• Comprehensive analysis and insights gained from long-term experience of the Spanish DILI registry.

  2021cited by this paper
• Causal inference with observational data: the need for triangulation of evidence

  2021cited by this paper
• ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.

  2021cited by this paper
• Lymphocyte Profile and Immune Checkpoint Expression in Drug‐Induced Liver Injury: An Immunophenotyping Study

  2021cited by this paper
• Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.

  2020cited by this paper
• Treatment of Idiosyncratic Drug-Induced Liver Injury Using Steroids

  2020cited by this paper
• Corticosteroid therapy in drug‐induced liver injury: Pros and cons

  2019cited by this paper
• Prednisone is not beneficial for the treatment of severe drug-induced liver injury

  2019cited by this paper
• EASL Clinical Practice Guidelines: Drug-induced liver injury.

  2019cited by this paper
• Drug-induced liver injury

  2019cited by this paper
• Death and liver transplantation within 2 years of onset of drug‐induced liver injury

  2017cited by this paper
• Outcomes in Adults With Acute Liver Failure Between 1998 and 2013

  2016cited by this paper
• Beneficial effect of corticosteroids for patients with severe drug‐induced liver injury

  2016cited by this paper
• Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.

  2014cited by this paper
• Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury.

  2014cited by this paper
• Steroid use in acute liver failure

  2014cited by this paper
• A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

  2013cited by this paper
• Associations of Gender and Age with the Reporting of Drug‐Induced Hepatic Failure: Data from the VigiBase™

  2013cited by this paper
• Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury

  2011cited by this paper
• Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury

  2011cited by this paper
• An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

  2011cited by this paper
• Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies

  2010cited by this paper
• Matching methods for causal inference: A review and a look forward.

  2010cited by this paper
• Drug-Induced Liver Injury Network (DILIN) Prospective Study

  2009cited by this paper
• Phenotypic characterization of idiosyncratic drug‐induced liver injury: The influence of age and sex

  2009cited by this paper
• Characteristics of Patients with Idiosyncratic Drug Induced Liver Injury (DILI) Who Receive Systemic Corticosteroids: Initial Results from the U.S. DILI Network Prospective Study

  2008cited by this paper
• Outcome and prognostic markers in severe drug‐induced liver disease

  2005cited by this paper
• A model to predict survival in patients with end‐stage liver disease

  2001cited by this paper
• Validation of a combined comorbidity index.

  1994cited by this paper
• Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting.

  1990cited by this paper
• Criteria of drug-induced liver disorders. Report of an international consensus meeting.

  1990cited by this paper
• The central role of the propensity score in observational studies for causal effects

  1983cited by this paper
• European Association for the Study of the Liver

  1971cited by this paper

• Indian National Association for Study of the Liver Guidance Document on Difficult to Treat Autoimmune Hepatitis.

  2026cites this paper
• Navigating liver toxicity in the age of novel oncological agents

  2025cites this paper
• The DILI-Inpt prognostic score to Identify hospitalized Idiosyncratic DILI patients at risk for Adverse outcomes.

  2025cites this paper
• Drug Induced Liver Injury: Highlights and Controversies in the 2023 Literature

  2025cites this paper
• Liver Injury Following Intravenous Methylprednisolone Pulse Therapy in Multiple Sclerosis: The Experience from a Single Academic Liver Center

  2025cites this paper
• Prunella vulgaris polyphenols alleviate liver injury-uveitis comorbidity by regulating acylcarnitine via the S100A9-PP2A-AMPK pathway.

  2025cites this paper
• Infliximab-induced autoimmune-like hepatitis in a patient with Crohn’s disease: a case report

  2025cites this paper
• Remdesivir-Induced Hepatotoxicity: A Systematic Review of Clinical Evidence, Pharmacokinetics, and Safety Concerns

  2025cites this paper
• Natural History of Idiosyncratic Drug‐Induced Liver Injury and Prognostic Models

  2025cites this paper
• Glucocorticoids accelerate the reduction of disease severity and biochemical parameters in drug-induced liver injury: Assess the causal relationship using the updated RUCAM scale.

  2025cites this paper
• CNT as a robust delivery vehicle for anti-breast cancer drugs: A combined DFT and in-silico study.

  2025cites this paper
• Successful Use of Corticosteroids to Accelerate Recovery in Severe Autoimmune-like Hepatitis From Isoniazid

  2025cites this paper
• Ornidazole-Induced Liver Injury: The Clinical Characterization of a Rare Adverse Reaction and Its Implications from a Multicenter Study

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of autoimmune hepatitis.

  2025cites this paper
• Propensity score matching-based analysis of the effect of corticosteroids in treating severe drug-induced liver injury.

  2024cites this paper
• Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update

  2024cites this paper
• An optimized short‐term steroid therapy for chronic drug‐induced liver injury: A prospective randomized clinical trial

  2024cites this paper
• Drug-induced autoimmune-like hepatitis

  2024cites this paper
• Update zu medikamenteninduzierten Leberschäden

  2024cites this paper
• Drug-induced autoimmune-like hepatitis.

  2024cites this paper
• A state-of-the-art update on hepatotoxicity: Introduction to the special series on drug-induced liver injury

  2024cites this paper
• Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review

  2024cites this paper
• Successful corticosteroid therapy for severe liver injury secondary to herbal traditional Chinese medicine, Mega Defends X, assessed for causality by the updated RUCAM: A case report

  2024cites this paper
• Hellenic Association for the Study of the Liver (HASL): revised clinical practice guidelines for autoimmune hepatitis

  2024cites this paper
• Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report

  2023cites this paper
• Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

  2023cites this paper
• A 68-year-old woman with unexplained liver enzyme elevation and active chronic hepatitis: Beware of drug induced autoimmune like hepatitis.

  2023cites this paper
• Drug-induced cholestasis: causative agents and challenges in diagnosis and management

  2023cites this paper
• Idiosyncratic DILI and RUCAM under One Hat: The Global View

  2023cites this paper
• Response to: Letter to the Editor by Trinh et al. Drug‐induced liver injury registries are important

  2023cites this paper
• Multiple drugs

  2023cites this paper